# Desh Rakshak (NSE: DESHRAK) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/DESHRAK · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹19 Cr, it ranks 3610th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 25× trailing earnings, against a return on equity of 0.4% in FY15. In Q1 FY16, the quarter ended 30 Jun 2015, revenue was ₹1 Cr (−12.5% year on year) and net profit ₹0 Cr (−50.0%), on a consolidated basis. Promoters held 50.03% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹19 Cr |
| P/E (trailing) | 25 |
| ROE | 0.4% (FY15) |
| ROCE | 2.6% (FY15) |
| Debt to equity | 0.16 |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY16 | ₹1 Cr | −12.5% | ₹0 Cr | −50.0% | — |
| Q4 FY15 | ₹1 Cr | — | ₹0 Cr | — | — |
| Q1 FY15 | ₹1 Cr | — | ₹0 Cr | — | — |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY15 | ₹4 Cr | ₹0 Cr |
| FY14 | ₹4 Cr | ₹0 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 50.03%
- Non-institutions: 49.97%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Rekvina Labs](https://app.pivotnow.in/stock/VINRKLB) | — | ₹22 Cr | — | 0.0% |
| [Adeshwar Medite](https://app.pivotnow.in/stock/ADESHWAR) | — | ₹21 Cr | 11.1 | 5.6% |
| [Maitri](https://app.pivotnow.in/stock/MAITRI) | — | ₹19 Cr | 20 | 11.5% |
| [Nidan Lab](https://app.pivotnow.in/stock/NIDAN) | ₹12.65 | ₹18 Cr | — | — |
| [Vanta Bioscienc](https://app.pivotnow.in/stock/VANTABIO) | — | ₹17 Cr | 100 | 0.5% |
| [Venmax Drugs](https://app.pivotnow.in/stock/VENMAX) | — | ₹17 Cr | — | −0.2% |

## Questions and answers

### What is the market cap of Desh Rakshak?

Desh Rakshak's market capitalisation is ₹19 Cr (₹19 Cr) at the 22 Oct 2026 close, ranking 3610th among the NSE companies Pivot tracks.

### What is the P/E ratio of Desh Rakshak?

Desh Rakshak trades at a trailing P/E of 25. The median P/E of the 3 closest Pharma & Healthcare peers by market cap is 20.

### What is the ROE and ROCE of Desh Rakshak?

Return on equity was 0.4% in FY15 and return on capital employed was 2.6% in FY15 (consolidated figures).

### Is Desh Rakshak a debt-free company?

No. Desh Rakshak's debt-to-equity ratio was 0.16 in FY15, with total debt of ₹1 Cr.

### What were Desh Rakshak's latest quarterly results?

For Q1 FY16 (quarter ended 30 Jun 2015), Desh Rakshak reported revenue of ₹1 Cr, −12.5% year on year, and net profit of ₹0 Cr, −50.0% year on year.

### What is the shareholding pattern of Desh Rakshak?

As of 30 Jun 2026: promoters 50.03%, non-institutions 49.97%.

### Who are Desh Rakshak's competitors?

The listed Pharma & Healthcare companies closest to Desh Rakshak by market cap are Rekvina Labs, Adeshwar Medite, Maitri, Nidan Lab, Vanta Bioscienc and Venmax Drugs.

### Is Desh Rakshak a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Desh Rakshak's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on DESHRAK against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.